Fanconi Anemia

Genetics and Pathophysiology

• Inherited bone marrow failure syndrome characterized by genomic instability.
• Autosomal recessive inheritance primarily represents over 99% of cases.
• Rare X-linked recessive (FANCB) and autosomal dominant (FANCR/RAD51) inheritance identified.
• Twenty-two FANC genes identified; FANCA, FANCC, and FANCG represent over 90% of cases.
• Gene products assemble to form core complex necessary for DNA damage repair.
• Core complex monoubiquitinates FANCD2 and FANCI, stabilizing stalled replication forks.
• Defective pathway results in faulty DNA damage response.
• Cells exhibit extreme hypersensitivity to DNA crosslinking agents, oxygen-free radicals, and ionizing radiation.

Epidemiology

• Estimated frequency represents 1 in 200,000 in most populations.
• Higher carrier frequencies noted in specific populations due to founder effects.
• Ashkenazi Jews feature high FANCC and FANCD1 mutations.
• Afrikaners and Spanish Gypsies feature high FANCA mutations.

Clinical Manifestations

Somatic Anomalies

• Up to 40% of patients lack obvious physical abnormalities.
• Skeletal anomalies: short stature, abnormal radii, thumb deformities.
• Radial ray defects represent terminal defects; abnormal radii strictly associate with thumb anomalies (hypoplastic, supernumerary, bifid, absent).
• Skin features: generalized hyperpigmentation, café-au-lait spots, hypopigmented areas.
• Craniofacial anomalies: microcephaly, microphthalmia, epicanthal folds, micrognathia, abnormal ears.
• Renal malformations: ectopic, pelvic, horseshoe, hypoplastic, or absent kidneys.
• Genitourinary defects: male hypogenitalism, hypospadias, female reproductive tract malformations, reduced fertility.
• VACTERL or VACTERL-H associations present in affected neonates.
• Endocrine dysfunction: growth hormone deficiency, hypothyroidism.

Hematologic Findings

• Median age at hematologic presentation occurs at 8-10 years.
• Initial manifestations include macrocytosis, elevated fetal hemoglobin, and thrombocytopenia.
• Progresses gradually to severe pancytopenia and aplastic anemia.

Malignancy Predisposition

• Exceedingly high risk of malignant transformation.
• Cumulative incidence of clonal/malignant myeloid transformation (myelodysplastic syndrome, acute myeloid leukemia) reaches 75% by age 18 years.
• High relative risk of solid tumors developing at remarkably young ages.
• Squamous cell carcinomas frequently affect head, neck, esophagus, vulva, anus, and cervix.
• Human papillomavirus suspected in squamous cell carcinoma pathogenesis.
• Liver tumors (adenomas, hepatomas) associate strongly with prolonged androgen therapy.

Diagnostic Evaluation

Primary Screening Modalities

• Chromosome breakage test serves as gold standard screening.
• Peripheral blood lymphocytes cultured with DNA crosslinking agents (diepoxybutane or mitomycin C).
• Exhibits increased spontaneous chromatid breaks, gaps, radials, endoreduplications, and exchanges.
• Fibroblast testing indicated if somatic mosaicism suspected; mosaicism produces false-negative lymphocyte results.
• Flow cytometry demonstrates increased G2/M cell cycle arrest upon exposure to alkylating agents.

Definitive Genetic Testing

• Next-generation sequencing gene panels or whole-exome sequencing provide definitive diagnosis.
• Complementation group analysis and targeted mutation analysis utilized historically.

Hematologic Assessment

• Complete blood counts reveal progressive cytopenias and macrocytosis.
• Bone marrow aspirate and biopsy demonstrate hypocellularity, fatty replacement, and dysplastic precursors.

Differential Diagnosis

• Dyskeratosis congenita: distinguished by extreme telomere shortening and classic mucocutaneous triad (nail dystrophy, oral leukoplakia, reticular skin pigmentation).
• Diamond-Blackfan anemia: presents typically in first year of life as isolated pure red cell aplasia with normal chromosome breakage studies.

Management Strategies

Medical and Supportive Care

• Serial monitoring of blood counts every 3-4 months initially.
• Minimize red cell and platelet transfusions to prevent allosensitization and iron overload.
• Utilize leukocyte-depleted, irradiated, single-donor blood products.
• Androgen therapy (oxymetholone, danazol): improves bone marrow function in approximately 50-70% of patients.
• Androgens require careful tapering to lowest effective dose; side effects include virilization, peliosis hepatis, and liver tumors.
• Cytokine therapy (granulocyte colony-stimulating factor): used for severe neutropenia, though carries theoretical risk of promoting clonal myeloid expansion.

Curative Therapy

• Hematopoietic stem cell transplantation remains the exclusive curative therapy for hematologic manifestations.
• Human leukocyte antigen typing indicated at diagnosis for patient and siblings.
• Standard myeloablative conditioning highly toxic due to DNA repair defect.
• Reduced-intensity conditioning regimens (fludarabine, low-dose cyclophosphamide, antithymocyte globulin) improve survival and reduce toxicity.
• Stem cell transplantation does not cure solid tumor predisposition; actually increases post-transplant risk of squamous cell carcinomas.

Novel Therapies

• Gene therapy utilizing lentiviral vectors for FANCA correction currently under experimental clinical trials.

Long-Term Surveillance Protocol

• Administration of human papillomavirus quadrivalent vaccine strongly advised to mitigate squamous cell carcinoma risk.
• Avoid exposure to environmental mutagens, insecticides, and unnecessary radiologic imaging.

Prognosis

• Hematologic survival significantly improved with modern reduced-intensity hematopoietic stem cell transplantation.
• Actuarial long-term disease-free survival for matched sibling transplantation approaches 90%.
• Morbidity and mortality heavily driven by nonhematologic solid tumors emerging in the third and fourth decades of life.
• Transplant recipients face accelerated risk of head and neck cancers, occurring approximately 15 years earlier than non-transplanted patients.